Cogent Biosciences, Inc.
Cogent Biosciences, Inc. (NASDAQ: COGT) is a clinical-stage biotechnology company focused on developing precision therapies for genetically defined diseases. The company's approach centers on designing rational precision medicines that target the underlying genetic causes of disease to improve patient outcomes. From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Cogent Biosciences, Inc. does
In the company’s own words
Cogent Biosciences, Inc. (NASDAQ: COGT) is a clinical-stage biotechnology company focused on developing precision therapies for genetically defined diseases. The company's approach centers on designing rational precision medicines that target the underlying genetic causes of disease to improve patient outcomes.
The company's most advanced program is bezuclastinib, also known as CGT9486, a highly selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation and other mutations in KIT exon 17. Bezuclastinib is being developed to treat patients with Systemic Mastocytosis, including both Non-Advanced Systemic Mastocytosis and Advanced Systemic Mastocytosis, as well as gastrointestinal stromal tumors. In 2025, Cogent reported positive top-line results from registrational trials in each of these indications and submitted its first New Drug Application for bezuclastinib in patients with Non-Advanced Systemic Mastocytosis in December 2025. The company expects to launch bezuclastinib commercially in the United States in the second half of 2026, pending regulatory approval.
Beyond bezuclastinib, Cogent is building a pipeline of additional precision therapies. The company has an ongoing Phase 1 study of CGT4859, a novel FGFR2/3 inhibitor, and initiated a Phase 1 study of CGT4255, a CNS-penetrant, selective mutant ErbB2 inhibitor. The company is also developing CGT6297, a PI3Kα inhibitor, with Phase 1 initiation expected in the first quarter of 2026. The Cogent Research Team, based in Boulder, Colorado, is advancing preclinical programs targeting KRAS and JAK2 mutations, with plans to submit investigational new drug applications for these programs in 2026.
Cogent has assembled a management team with extensive experience in research, development, manufacturing, and commercialization of pharmaceutical products, particularly precision medicines for genetically defined diseases. The company is building an internal commercial organization to support the anticipated launch of bezuclastinib. More information about the company is available at www.cogentbio.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- WALTHAM, MA
- Fiscal year end
- December
- CIK
- 1622229
- SIC
- 2834
Financial performance, year by year
Fiscal 2018–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Cogent Biosciences, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Cogent Biosciences, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Cogent Biosciences, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Cogent Biosciences, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Cogent Biosciences, Inc.'s last four quarterly filings that the numbers alone won't show?”